XeroThera has developed breakthrough technologies for tissue engineering and the controlled and targeted delivery of drugs and biological molecules. The technology is the result of twenty years of fundamental studies on sol gel processed, nanoporous, oxide-based materials in academic laboratories at the University of Pennsylvania, Philadelphia.
XeroThera’s unique delivery concepts make it possible to treat conditions that currently defy solutions. It has formulated a pipeline of product concepts that address the prevention and treatment of surgical infections, bone infections, and resistant (“MRSA”) infection; it can also develop tissue engineering scaffolds, and address surgical pain treatment and diabetes wound treatment.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Avenue Du Parc Industriel 89, Milmort,liège B 4041,belgium
- Industry
- Medical Equipment Manufacturing
- NAICS
-
Medical Equipment and Supplies ManufacturingSurgical and Medical Instrument ManufacturingSurgical Appliance and Supplies ManufacturingDental Equipment and Supplies ManufacturingOphthalmic Goods ManufacturingDental Laboratories
- Website
- http://www.xerotherainc.com
- Keywords
- Xerogel, Synthetic Graft, Controlled Release.
- HQ
- Milmort , Liège
Xerothera Europe Questions
Xerothera Europe's website is http://www.xerotherainc.com
Xerothera Europe's LinkedIn profile is https://be.linkedin.com/company/xerothera-europe
Xerothera Europe has
3 employees.
View email and phone details for 3
employees at Xerothera Europe.
Xerothera Europe's industry is
Medical Equipment Manufacturing
Xerothera Europe's top competitors are
Novalon Pharma,
Neuralis,
Merck Life Science,
Axeo,
Xerothera,
Phasya (Acquired By Tobii),
Exothera,
Bourgeois & Cie,
Domaine Des Thermes Awans,
Sodimed.
Xerothera Europe's categories are Medical Equipment Manufacturing
Xerothera Europe's founding year is 2018
